Please enable Javascript
Advanced Urothelial Carcinoma
Advertisement
EV-302: EV Plus Pembrolizumab Improves OS, PFS in Untreated, Advanced Urothelial Carcinoma
Zachary Bessette
Advanced Urothelial Carcinoma
|
September 22, 2023
The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.
Read More
Association of Squamous Histology and Clinical Outcomes, Molecular Profiling in mUC
Ivan de Kouchkovsky, MD
Advanced Urothelial Carcinoma
|
September 19, 2023
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
View More
Examining Squamous Urothelial Carcinoma Responsiveness to Novel Therapies
Ivan de Kouchkovsky, MD
Advanced Urothelial Carcinoma
|
September 19, 2023
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
View More
EV-301 2-Year Follow-up Shows Consistent Benefit of EV Over Chemotherapy for Urothelial Carcinoma
Emily Menendez
Advanced Urothelial Carcinoma
|
September 15, 2023
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Read More
FDA Round-Up: Erdafitinib for mUC, Enzalutamide for nmCSPC
Zachary Bessette
Advanced Urothelial Carcinoma
|
August 30, 2023
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
Read More
DDR Mutations Not Linked to Clinical Benefit of Olaparib in mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
August 29, 2023
Somatic alterations in DDR genes are common in patients with advanced urothelial cancer.
Read More
Drs. Gupta, Koshkin on EV-103 Cohort K Results and Toxicities
Shilpa Gupta, MD
ASCO 2023
|
August 4, 2023
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
View More
Drs. Gupta, Koshkin on EV-103 Design and Long-term Cohort A Results for Patients With aUC
Shilpa Gupta, MD
ASCO 2023
|
August 4, 2023
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
View More
EV Plus Pembrolizumab Demonstrates High cORR, Durable Responses in Cisplatin-Ineligible Patients With mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
August 2, 2023
Enfortumab vedotin and pembrolizumab have shown a survival benefit as individual treatments in locally advanced and mUC.
Read More
Biomarkers of Response to SG and EV in Advanced Urothelial Carcinoma: Analysis of the UNITE Study
Tanya Jindal
ASCO 2023
|
July 28, 2023
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
View More
CheckMate-901 Shows OS, PFS Benefit of Nivolumab Plus Cisplatin-Based Chemotherapy for mUC
Emily Menendez
Advanced Urothelial Carcinoma
|
July 13, 2023
Nivolumab and cisplatin-based chemotherapy administered before nivolumab alone demonstrates significant OS and PFS benefit.
Read More
Drs. Loriot, Koshkin on Results From Cohort 1 of the THOR Study
Yohann Loriot, MD, PhD
ASCO 2023
|
June 16, 2023
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
View More
Drs. Powles, Koshkin on the Q-TWiST Analysis for JAVELIN Bladder 100
Thomas Powles, MBBS, MRCP, MD
ASCO 2023
|
June 15, 2023
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
View More
Drs. Lerner, Koshkin on SWOG S1011 Results for Lymphadenectomy for Metastatic Urothelial Carcinoma
Seth Lerner, MD, FACS
ASCO 2023
|
June 15, 2023
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
View More
Drs. Friedlander, Koshkin on Long-Term Follow-Up of EV-103
Terence Friedlander, MD
ASCO 2023
|
June 15, 2023
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
View More
Drs. Siefker-Radtke, Koshkin on the NORSE Study for Metastatic Urothelial Carcinoma
Arlene O. Siefker-Radtke, MD
ASCO 2023
|
June 15, 2023
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
View More
IMvigor130: Updated OS Data From the Final Analysis
Zachary Bessette
ASCO 2023
|
June 2, 2023
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
Read More
KEYNOTE-361: Complete Response Outcomes With First-line Pembrolizumab or Platinum-Based Chemotherapy
Emily Menendez
ASCO 2023
|
June 1, 2023
A post hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Read More
Drs. Koshkin, Basu on Clinical Practice Patterns for Adjuvant Therapy of ctDNA-Positive MIBC
Arnab Basu, MD, MPH, FACP
Advanced Urothelial Carcinoma
|
June 1, 2023
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
View More
Drs. Koshkin, Basu on ctDNA and MRD Considerations for Adjuvant Therapy After Radical Cystectomy
Arnab Basu, MD, MPH, FACP
Advanced Urothelial Carcinoma
|
June 1, 2023
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
View More
Load More
Advertisement
Advertisement
Advertisement